DDInter1476 DDInter1329
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oliceridine
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Pirbuterol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Pirbuterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Pirbuterol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Pirbuterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pirbuterol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Pirbuterol (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pirbuterol (Compound) resembles Nadolol (Compound) and Nadolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pirbuterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Oliceridine
Pirbuterol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pirbuterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine